We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
Diagnoses you can count on®
PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.
PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:
Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.
Daniel Arber, MD – Topics TBD
Read More »Endometrial Cancer, Relevant Issues and Mesenchymal Uterine Neoplasms, Soundtables
Read More »Please read the attached letter for additional information.
Read More »